For Doctors in a Hurry
- Clinicians lack clear evidence regarding the cross-diagnostic efficacy of noninvasive brain stimulation for reducing patient suicidal ideation.
- The researchers conducted a network meta-analysis of 58 randomized controlled trials evaluating various brain stimulation interventions across psychiatric conditions.
- Bitemporal electroconvulsive therapy reduced suicidal ideation compared to sham, while repetitive stimulation plus escitalopram also showed significant benefit.
- The authors concluded that bitemporal electroconvulsive therapy and repetitive stimulation combined with antidepressants are effective for managing suicidal ideation.
- Physicians should prioritize these specific combined interventions, as nonconvulsive stimulation alone demonstrated no clinical benefit over sham procedures.
Refining Neuromodulation for Acute Suicide Risk
Managing suicidal ideation remains a critical challenge in clinical practice because conventional pharmacotherapy and psychotherapy typically require several weeks to demonstrate therapeutic effects [1, 2]. While noninvasive brain stimulation techniques such as repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS) are established treatments for treatment-resistant depression, their efficacy in rapidly reducing suicide risk across varied psychiatric diagnoses remains poorly defined [3, 4, 5, 6]. Current consensus guidelines highlight the necessity for targeted interventions that can supplement standard care during acute crises [7]. A recent network meta-analysis of 58 randomized controlled trials now clarifies these roles, finding that bitemporal electroconvulsive therapy (ECT) and high-frequency rTMS combined with selective serotonin reuptake inhibitors (SSRIs) significantly reduce suicidal ideation, whereas nonconvulsive stimulation alone showed no benefit over sham [8]. These findings address the clinical uncertainty regarding which specific modalities offer a direct anti-suicidal effect independent of general symptom reduction [4].
The researchers conducted a systematic review and network meta-analysis, a statistical method that allows for the comparison of multiple treatments simultaneously by calculating indirect comparisons even if they have not been tested head to head in a single trial. This investigation spanned various psychiatric conditions and the entire lifespan, searching Embase, MEDLINE, PsycINFO, CINAHL, and the Cochrane CENTRAL Database from their inception through March 2023. To ensure clinical relevance, the inclusion criteria required randomized controlled trials featuring at least one noninvasive brain stimulation arm and an outcome derived from a suicide-specific measure or the suicide item of a standardized clinical scale. Studies were excluded if they focused solely on invasive stimulation or if they specifically excluded participants with suicidal ideation at the outset, ensuring the data reflected patients with active clinical need. From the initial search, 75 studies met the inclusion criteria for the systematic review, and 58 of these trials provided sufficient data for inclusion in the meta-analyses. The researchers utilized standardized mean differences, specifically Hedges' g (a measure of effect size that accounts for differences in sample sizes to provide a more accurate estimate of treatment impact), to determine the comparative efficacy of the interventions. The analysis was structured into three distinct networks to isolate specific clinical scenarios: Network 1 focused on patients with suicidal ideation at baseline, Network 2 included all identified trials regardless of baseline status, and Network 3 examined stimulation when paired with the initiation of new pharmacotherapy.
Efficacy of Convulsive and Combined Therapies
The second analysis, designated as Network 2, included 25 randomized controlled trials and evaluated the broad efficacy of various stimulation modalities across different patient populations. Within this cohort, bitemporal electroconvulsive therapy (ECT), which involves the application of electrical stimulus to both temporal lobes to induce a therapeutic seizure, was the only intervention that was favorable compared to sham stimulation for reducing suicidal ideation. In contrast, all other noninvasive brain stimulation interventions evaluated in Network 2 showed no benefit over sham procedures. This finding suggests that for patients receiving monotherapy with brain stimulation, the convulsive nature of bitemporal electroconvulsive therapy remains a critical factor in achieving a measurable reduction in suicidal thoughts, likely due to the more profound and widespread neurobiological changes induced by a generalized seizure compared to focal sub-threshold stimulation. The researchers further examined the synergy between neuromodulation and medication in Network 3, which included five randomized controlled trials. This analysis focused on the initiation of pharmacotherapy alongside brain stimulation. The results demonstrated that repetitive transcranial magnetic stimulation (TMS) applied to the left dorsolateral prefrontal cortex (DLPFC), an area of the brain responsible for executive function and emotional regulation, plus escitalopram significantly reduced suicidal ideation when compared to a control group receiving sham stimulation plus a selective serotonin reuptake inhibitor (SSRI). This specific combination highlights a potential therapeutic pathway for clinicians managing acute suicidal risk, as the data indicate that high-frequency repetitive transcranial magnetic stimulation is most effective when integrated with standard antidepressant medication. Collectively, these findings support bitemporal electroconvulsive therapy and high-frequency repetitive transcranial magnetic stimulation combined with SSRIs as effective interventions for the clinical management of suicidal ideation. The meta-analysis underscores a vital distinction for practicing physicians: while convulsive therapy and combined TMS-medication protocols show efficacy, nonconvulsive brain stimulation without concurrent pharmacotherapy shows no benefit over sham stimulation. This distinction is particularly relevant for treatment planning in psychiatric settings, as it clarifies that nonconvulsive modalities like transcranial magnetic stimulation should not be relied upon as standalone treatments for the rapid reduction of suicidal thoughts.
Limitations in Monotherapy and Accelerated Protocols
The researchers specifically evaluated the efficacy of intensive stimulation schedules in Network 1, which included three randomized controlled trials that utilized accelerated transcranial magnetic stimulation (TMS). These protocols, which involve delivering multiple stimulation sessions per day to the left dorsolateral prefrontal cortex (DLPFC), were tested in patients who presented with suicidal ideation at baseline. Despite the increased frequency of treatment, the analysis found that accelerated TMS over the left DLPFC showed no difference from sham TMS for the reduction of suicidal ideation. This suggests that simply increasing the dose or frequency of transcranial magnetic stimulation does not necessarily translate to a rapid anti-suicidal effect when used as a standalone intervention, a finding that may disappoint clinicians hoping for a faster non-convulsive alternative to ECT. Several limitations must be considered when applying these findings to clinical practice. The researchers noted that the evidence base remains thin for certain applications, citing small study numbers in networks 1 and 3 as a factor that may limit the precision of the effect estimates. Furthermore, the analysis of network 2 was limited by large heterogeneity in study design and suicidal ideation outcomes, reflecting the diverse ways in which researchers measure and report suicidal thoughts across different clinical trials. It is also important to note that the participants in networks 2 and 3 focused primarily on patients with depression, which may limit the generalizability of these results to patients experiencing suicidal crises in the context of other psychiatric conditions, such as personality disorders or substance use disorders. Ultimately, the meta-analysis clarifies the boundaries of noninvasive brain stimulation in acute suicide prevention. The data indicate that nonconvulsive noninvasive brain stimulation without pharmacotherapy shows no benefit over sham stimulation for the reduction of suicidal ideation. For the practicing physician, this reinforces the necessity of maintaining standard pharmacological treatments, such as selective serotonin reuptake inhibitors, when utilizing transcranial magnetic stimulation. While bitemporal electroconvulsive therapy remains a potent tool for rapid intervention, other nonconvulsive modalities appear to require the synergistic effect of medication to achieve meaningful clinical improvements in suicidal ideation.
References
1. Cui L, Li S, Wang S, et al. Major depressive disorder: hypothesis, mechanism, prevention and treatment. Signal Transduction and Targeted Therapy. 2024. doi:10.1038/s41392-024-01738-y
2. Tikka SK, Siddiqui MA, Garg S, Pattojoshi A, Gautam M. Clinical Practice Guidelines for the Therapeutic Use of Repetitive Transcranial Magnetic Stimulation in Neuropsychiatric Disorders. Indian Journal of Psychiatry. 2023. doi:10.4103/indianjpsychiatry.indianjpsychiatry_492_22
3. Zheng EZ, Wong NML, Yang ASY, Lee TM. Evaluating the effects of tDCS on depressive and anxiety symptoms from a transdiagnostic perspective: a systematic review and meta-analysis of randomized controlled trials. Translational Psychiatry. 2024. doi:10.1038/s41398-024-03003-w
4. Chen Y, Magnin C, Brunelin J, Leaune E, Fang Y, Poulet E. Can seizure therapies and noninvasive brain stimulations prevent suicidality? A systematic review.. Brain and behavior. 2021. doi:10.1002/brb3.2144
5. Lefaucheur J, Alemán A, Baeken C, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018). Clinical Neurophysiology. 2020. doi:10.1016/j.clinph.2019.11.002
6. Valiengo L, Maia A, Cotovio G, et al. Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Older Adults: Systematic Review and Meta-analysis. The Journals of Gerontology Series A. 2021. doi:10.1093/gerona/glab235
7. Trapp NT, Purgianto A, Taylor JJ, et al. Consensus review and considerations on TMS to treat depression: A comprehensive update endorsed by the National Network of Depression Centers, the Clinical TMS Society, and the International Federation of Clinical Neurophysiology. Clinical Neurophysiology. 2024. doi:10.1016/j.clinph.2024.12.015
8. Traynor JM, Koudys JW, Weichel M, et al. The Comparative Efficacy of Noninvasive Brain Stimulation for Suicidal Ideation: A Network Meta-Analysis.. The American journal of psychiatry. 2026. doi:10.1176/appi.ajp.20250753
